{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:44:54Z","timestamp":1792125894725,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119401","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:45:03Z","timestamp":1791416703000},"page":"119401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Design of 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine derivatives targeting the DFG-out conformation of VEGFR-2: Synthesis, biological evaluations, and molecular modeling approaches"],"prefix":"10.1016","volume":"321","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-7399","authenticated-orcid":false,"given":"Abdulrahman M.","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-4017","authenticated-orcid":false,"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0434-2369","authenticated-orcid":false,"given":"Mohamed R.","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-5280","authenticated-orcid":false,"given":"Ghada F.","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4205-0538","authenticated-orcid":false,"given":"Mohamed A.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ayman","family":"El-Zahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"Abou-Seri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119401_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107829","article-title":"Design, synthesis, and in silico insights of novel N\u2019-(2-oxoindolin-3-ylidene) piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors","volume":"153","author":"Eldehna","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib2","series-title":"Palliative Care in the Arab World","first-page":"381","author":"Al-Shamsi","year":"2022"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119401_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up\u2010to\u2010date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejmech.2026.119401_bib4","first-page":"557","volume":"20182020","author":"Ferlay","year":"2020"},{"key":"10.1016\/j.ejmech.2026.119401_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1323350","article-title":"Vascular co-option in resistance to anti-angiogenic therapy","volume":"13","author":"Ribatti","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119401_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900340","article-title":"Design, synthesis, and molecular docking of novel 2\u2010arylbenzothiazole multiangiokinase inhibitors targeting breast cancer","volume":"353","author":"Abdel\u2010Mohsen","year":"2020","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2026.119401_bib7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/0471728780.ch26","article-title":"Protein kinase inhibitors drug discovery","author":"Parang","year":"2005","journal-title":"Drug discovery handbook"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119401_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119401_bib9","series-title":"Protein Tyrosine Kinases: from Inhibitors to Useful Drugs","first-page":"1","article-title":"Protein tyrosine kinases as targets for cancer and other indications","author":"Pearson","year":"2006"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0969-2126(00)00036-8","article-title":"Three protein kinase structures define a common motif","volume":"2","author":"Taylor","year":"1994","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.119401_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119401_bib12","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119401_bib13","series-title":"Antiangiogenic Agents in Cancer Therapy","first-page":"205","article-title":"Tumor blood vessels: structure, function and classification","author":"Fu","year":"2007"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119401_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119401_bib15","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6918","article-title":"VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside","volume":"7","author":"Arjaans","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119401_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.ejmech.2026.119401_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/cells14191555","article-title":"The role of growth factors and signaling pathways in ovarian angiogenesis","volume":"14","author":"Jankowska-Ziemak","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119401_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119401_bib21","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1039\/D6RA00037A","article-title":"Pyrazolo [3, 4-d] pyrimidine derivatives as VEGFR-2 and EGFRT790M dual inhibitors: design, docking, ADMET, synthesis and anticancer evaluations","volume":"16","author":"Aziz","year":"2026","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119401_bib22","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2018.11.061","volume":"163","author":"Eldehna","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119401_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119401_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14656566.2012.679930","article-title":"Sorafenib in liver cancer","volume":"13","author":"Woo","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119401_bib26","series-title":"Diaryl Ureas with Kinase Inhibiting Activity","author":"Wilhelm","year":"2004"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73\u20104506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119401_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-21-2334","article-title":"FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma","volume":"28","author":"Chang","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"29","key":"10.1016\/j.ejmech.2026.119401_bib29","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2174\/092986708786848613","article-title":"Small molecules ATP-competitive inhibitors of FLT3: a chemical overview","volume":"15","author":"Schenone","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119401_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","article-title":"Lenvatinib: first global approval","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119401_bib32","doi-asserted-by":"crossref","first-page":"16976","DOI":"10.1039\/D6RA00792A","article-title":"Recent green approaches for the synthesis of thienopyrimidine scaffolds: an overview (2007\u20132025)","volume":"16","author":"Rabeh","year":"2026","journal-title":"RSC Adv."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119401_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700242","article-title":"Medicinal attributes of thienopyrimidine based scaffold targeting tyrosine kinases and their potential anticancer activities","volume":"350","author":"Ghith","year":"2017","journal-title":"Arch. Pharmazie"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib34","first-page":"1","article-title":"The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer","volume":"51","author":"Cheng","year":"2024","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan\u2013class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119401_bib36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-009-1076-8","article-title":"SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo","volume":"65","author":"Arbitrario","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119401_bib37","article-title":"Dual PI3K and HDAC inhibitor, CUDC-907, effectively inhibits endometrial cancer growth in vitro and in vivo","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119401_bib38","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1021\/acs.jmedchem.1c00678","article-title":"Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105019","article-title":"Discovery of potent thieno [2, 3-d] pyrimidine VEGFR-2 inhibitors: design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations","volume":"113","author":"Elrazaz","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109693","article-title":"Targeting VEGFR-2 with piperazine bridged Indolin-2-one derivatives","author":"Zengin","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2015.10.053","article-title":"1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation","volume":"107","author":"Abou-Seri","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib42","first-page":"587","article-title":"New series of VEGFR-2 inhibitors and apoptosis enhancers: design, synthesis and biological evaluation","author":"Abdallah","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/molecules29010068","article-title":"Synthetic approaches to piperazine-containing drugs approved by FDA in the period of 2011\u20132023","volume":"29","author":"Romanelli","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119401_bib44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1039\/D3MD00506B","article-title":"Role of heterocycles in inhibition of VEGFR-2\u2013a recent update (2019\u20132022)","volume":"15","author":"Dorababu","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119401_bib45","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1021\/jm0611051","article-title":"Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors","volume":"50","author":"Hasegawa","year":"2007","journal-title":"J. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2026.119401_bib46","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119401_bib47","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/ph18121875","article-title":"Discovery of novel piperidinyl-based benzoxazole derivatives as anticancer agents targeting VEGFR-2 and c-Met kinases","volume":"18","author":"Eldehna","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"32","key":"10.1016\/j.ejmech.2026.119401_bib48","doi-asserted-by":"crossref","first-page":"22122","DOI":"10.1039\/D3RA04182D","article-title":"Design, synthesis, in silico studies, and biological evaluation of novel pyrimidine-5-carbonitrile derivatives as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers","volume":"13","author":"Saleh","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119401_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejmech.2016.02.029","article-title":"Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives","volume":"113","author":"Eldehna","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmech.2012.02.035","article-title":"Thieno [2, 3-d] pyrimidinedione derivatives as antibacterial agents","volume":"51","author":"Dewal","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1080\/14756366.2021.1933465","article-title":"Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine\u2013hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer","volume":"36","author":"Abdel-Atty","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib52","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bioorg.2018.09.001","article-title":"Identification of new pyrrolo [2, 3-d] pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: design, synthesis, biological evaluation and molecular modeling","volume":"81","author":"Adel","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib53a","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.27236","article-title":"Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma","volume":"60","author":"Peng","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.119401_bib53b","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/me.2007-0319","article-title":"Vascular endothelial growth factor receptor-2 expression is down-regulated by 17\u03b2-estradiol in MCF-7 breast cancer cells by estrogen receptor \u03b1\/Sp proteins","volume":"22","author":"Higgins","year":"2008","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2796.2010.02282.x","article-title":"Cell cycle and cell death in disease: past, present and future","volume":"268","author":"Zhivotovsky","year":"2010","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119401_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways targeted cancer therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharmaceut. Bull."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119401_bib57","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.12-12-1395","article-title":"Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas","volume":"12","author":"Lefranc","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119401_bib58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1054\/bjoc.2001.1876","article-title":"Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells","volume":"85","author":"Pidgeon","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119401_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0165-6147(03)00026-9","article-title":"Cell-cycle dysregulation and anticancer therapy","volume":"24","author":"Stewart","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119401_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100030","article-title":"Cell cycle dysregulation in cancer","volume":"77","author":"Glaviano","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib61","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1021\/jm049538w","article-title":"Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors","volume":"48","author":"Harris","year":"2005","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119401_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/jm061107l","article-title":"Evolution of a highly selective and potent 2-(pyridin-2-yl)-1, 3, 5-triazine Tie-2 kinase inhibitor","volume":"50","author":"Hodous","year":"2007","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119401_bib63","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1021\/jm070034i","article-title":"Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors","volume":"50","author":"Potashman","year":"2007","journal-title":"J. Med. Chem."},{"issue":"9_Supplement","key":"10.1016\/j.ejmech.2026.119401_bib64","article-title":"PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2","volume":"67","author":"Marrone","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119401_bib65","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/jm701098w","article-title":"Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors","volume":"51","author":"Weiss","year":"2008","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119401_bib66","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1021\/jm701097z","article-title":"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation","volume":"51","author":"Harmange","year":"2008","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119401_bib67","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1016\/j.bmc.2010.08.017","article-title":"Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo [3, 2-d] pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation","volume":"18","author":"Oguro","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2026.119401_bib68","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119401_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115707","article-title":"Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties","volume":"259","author":"Saied","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119401_bib70","first-page":"123","article-title":"Clinical advances in the development of novel VEGFR2 inhibitors","volume":"2","author":"Fontanella","year":"2014","journal-title":"Ann. Transl. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119401_bib71","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1080\/07391102.2023.2294170","article-title":"New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro, and in silico studies","volume":"43","author":"Yousef","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.119401_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108159","article-title":"Design and synthesis of new 1,2,3-triazole derivatives as VEGFR-2\/telomerase downregulatory candidates endowed with apoptotic potential for cancer treatment","volume":"156","author":"Al-Karmalawy","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108526","article-title":"Design and synthesis of novel 2-S-alkylated Quinazolinones as dual BRAFV600E and EGFR inhibitors in melanoma: mechanistic insights from apoptosis and cell cycle modulation","volume":"161","author":"El-Shafey","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119401_bib74","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/plants11172192","article-title":"Potential apoptotic activities of Hylocereus undatus peel and pulp extracts in MCF-7 and Caco-2 cancer cell lines","volume":"11","author":"Salam","year":"2022","journal-title":"Plants"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70339","article-title":"Benzimidazole\u2010based VEGFR\u20102 inhibitors inspired by sorafenib: Synthesis, biological evaluation, and mechanistic insights","volume":"87","author":"Dewidar","year":"2026","journal-title":"Drug Dev. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119401_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189513","article-title":"Probing the putative \u03b17 nAChR\/NMDAR complex in human and Murine cortex and hippocampus: different degrees of complex formation in healthy and Alzheimer brain tissue","volume":"12","author":"Elnagar","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119401_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108182","article-title":"New molecular hybrids integrated with quinoxaline and pyrazole structural motifs: VGFR2 inhibitors and apoptosis inducers","volume":"156","author":"Ismail","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119401_bib78","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1021\/acsmedchemlett.4c00438","article-title":"Furan-and furopyrimidine-based derivatives: synthesis, VEGFR-2 inhibition, and in vitro cytotoxicity","volume":"15","author":"Abd El-Haleem","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119401_bib79","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/pharmaceutics14081558","article-title":"Acetic acid mediated for one-pot synthesis of novel pyrazolyl s-Triazine derivatives for the targeted therapy of triple-negative breast tumor cells (MDA-MB-231) via EGFR\/PI3K\/AKT\/mTOR signaling cascades","volume":"14","author":"Shawish","year":"2022","journal-title":"Pharmaceutics"},{"issue":"36","key":"10.1016\/j.ejmech.2026.119401_bib80","doi-asserted-by":"crossref","first-page":"23644","DOI":"10.1039\/D2RA03549A","article-title":"Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition","volume":"12","author":"Thabet","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119401_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109087","article-title":"Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer","volume":"324","author":"Nafie","year":"2020","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119401_bib82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/cam.36224","article-title":"An introduction to the wound healing assay using live-cell microscopy","volume":"8","author":"Jonkman","year":"2014","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.ejmech.2026.119401_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118949","article-title":"Multi-target triazole\u2013benzopyrone hybrids modulating cholinergic dysfunction, oxidative stress, and neuroinflammation through GFAP\/NF-\u03baB\/APOE\/NLRP3 axis in Alzheimer's disease","author":"El-Mokaddem","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119401_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112066","article-title":"Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2\/5-LOX inhibitors","volume":"189","author":"Gedawy","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70211","article-title":"Rational design of triazole hydrazide derivatives with Imidazo [2, 1\u2010b] thiazole scaffolds as targeted EGFR inhibitors in NSCLC","volume":"87","author":"Elgohary","year":"2026","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2026.119401_bib86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2203389","article-title":"Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors","volume":"38","author":"Shaldam","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119401_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:55:05Z","timestamp":1792122905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":89,"alternative-id":["S0223523426008469"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119401","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine derivatives targeting the DFG-out conformation of VEGFR-2: Synthesis, biological evaluations, and molecular modeling approaches","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119401"}}